Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmunHER
2016-000435-41Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab and pertuzumab in breast cancer and inflammatory breast cancer (IBC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Tumor-infiltrating lymphocyte rate in residual disease. Started Dec 2020; status: completed.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancerinflammatory breast cancer (IBC)
Beyond the preview
Go deeper on 2016-000435-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000435-41.